These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17559748)

  • 1. Effect of NXY-059, a novel neuroprotectant, on the pharmacokinetics of a single dose of digoxin in healthy subjects.
    Huledal G; Nilsson D; Kågedal M; Reinholdsson I; Cheng YF; Svensson H; Borgå O; van Hout M
    Curr Med Res Opin; 2007 Jul; 23(7):1531-9. PubMed ID: 17559748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects.
    Wemer J; Cheng YF; Nilsson D; Reinholdsson I; Fransson B; Lanbeck Vallén K; Nyman L; Eriksson C; Björck S; Schulman S
    Curr Med Res Opin; 2006 Sep; 22(9):1813-23. PubMed ID: 16968585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.
    Cheng YF; Jiang J; Hu P; Reinholdsson I; Guo W; Asenblad N; Nilsson D
    Clin Ther; 2008 Dec; 30(12):2342-53. PubMed ID: 19167593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects.
    Watabe M; Cheng YF; Nilsson D; Itoh Y; Kumagai Y
    Curr Med Res Opin; 2007 Aug; 23(8):1849-57. PubMed ID: 17605894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke.
    Lees KR; Sharma AK; Barer D; Ford GA; Kostulas V; Cheng YF; Odergren T
    Stroke; 2001 Mar; 32(3):675-80. PubMed ID: 11239186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
    Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
    Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials.
    Diener HC; Lees KR; Lyden P; Grotta J; Davalos A; Davis SM; Shuaib A; Ashwood T; Wasiewski W; Alderfer V; Hårdemark HG; Rodichok L;
    Stroke; 2008 Jun; 39(6):1751-8. PubMed ID: 18369171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction.
    Rengelshausen J; Göggelmann C; Burhenne J; Riedel KD; Ludwig J; Weiss J; Mikus G; Walter-Sack I; Haefeli WE
    Br J Clin Pharmacol; 2003 Jul; 56(1):32-8. PubMed ID: 12848773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NXY-059 does not significantly interact with furosemide in healthy volunteers.
    Strid S; Nilsson D; Borgå O; Wemer J; Grahnén A
    J Clin Pharmacol; 2006 Dec; 46(12):1417-25. PubMed ID: 17101741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NXY-059: review of neuroprotective potential for acute stroke.
    Fong JJ; Rhoney DH
    Ann Pharmacother; 2006 Mar; 40(3):461-71. PubMed ID: 16507608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active renal secretion of NXY-059, a novel neuroprotectant, is mediated via an organic acid transporter.
    Cheng YF; Strid S; Borgå O; Nilsson D; Wemer J
    J Clin Pharmacol; 2007 Jul; 47(7):909-14. PubMed ID: 17585119
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial.
    Lyden PD; Shuaib A; Lees KR; Davalos A; Davis SM; Diener HC; Grotta JC; Ashwood TJ; Hardemark HG; Svensson HH; Rodichok L; Wasiewski WW; Ahlberg G;
    Stroke; 2007 Aug; 38(8):2262-9. PubMed ID: 17569876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover phase I study.
    Nilsson D; Wemer J; Cheng YF; Reinholdsson I; Englund G; Egberg N; Schulman S
    J Clin Pharmacol; 2007 Feb; 47(2):264-72. PubMed ID: 17244778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke.
    Lees KR; Barer D; Ford GA; Hacke W; Kostulas V; Sharma AK; Odergren T;
    Stroke; 2003 Feb; 34(2):482-7. PubMed ID: 12574564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NXY-059 for acute ischemic stroke.
    Lees KR; Zivin JA; Ashwood T; Davalos A; Davis SM; Diener HC; Grotta J; Lyden P; Shuaib A; Hårdemark HG; Wasiewski WW;
    N Engl J Med; 2006 Feb; 354(6):588-600. PubMed ID: 16467546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the concomitant administration of tamsulosin (0.8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin) in normal healthy subjects: a placebo-controlled evaluation.
    Miyazawa Y; Paul Starkey L; Forrest A; Schentag JJ; Kamimura H; Swarz H; Ito Y
    J Clin Pharm Ther; 2002 Feb; 27(1):13-9. PubMed ID: 11846858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
    Schwartz JI; De Smet M; Larson PJ; Verbesselt R; Ebel DL; Lins R; Lens S; Porras AG; Gertz BJ
    J Clin Pharmacol; 2001 Jan; 41(1):107-12. PubMed ID: 11144988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects.
    Feuring M; Lee Y; Orlowski LH; Michiels N; De Smet M; Majumdar AK; Petty KJ; Goldberg MR; Murphy MG; Gottesdiener KM; Hesney M; Brackett LE; Wehling M
    J Clin Pharmacol; 2003 Aug; 43(8):912-7. PubMed ID: 12953348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.
    Jönsson S; Cheng YF; Edenius C; Lees KR; Odergren T; Karlsson MO
    Clin Pharmacokinet; 2005; 44(8):863-78. PubMed ID: 16029070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do therapeutic doses of acarbose alter the pharmacokinetics of digoxin?
    Cohen E; Almog S; Staruvin D; Garty M
    Isr Med Assoc J; 2002 Oct; 4(10):772-5. PubMed ID: 12389338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.